Progress of immune checkpoint inhibitors in gastric cancer

Table 4 Clinical trials of immune checkpoint inhibitors combined with targeted therapy for gastric cancer

Immune checkpoint inhibitor	Target drug	Targets	Type of GC	Phase	Ref.
Pembrolizumab	Trastuzumab	HER-2	Advanced unresectable metastatic HER-2-positive GC	III	Lee et al[79]
Pembrolizumab	Trastuzumab	HER-2	Metastatic HER-2-positive GC	II	Janjigian et al[80]
Pembrolizumab	Margetuximab	HER-2	Locally advanced unresectable HER-2-positive metastatic GC, programmed death ligand 1 unselected, which had progressed after treatment with Trastuzumab combined with chemotherapy	I/II	Catenacci et al[81]
SHR-1210	Apatinib	VEGFR-2	GC/GEJ	II	Xu et al[82]
Pembrolizumab	Lenvatinib	VEGFR	Metastatic or recurrent GC/GEJ	II	Kawazoe et al[83]
Pembrolizumab	Lenvatinib	VEGFR	Advanced metastatic and/or unresectable GC which failed systemic therapy	II	Taylor et al[84]
Nivolumab	Regorafenib	VEGFR	Refractory advanced GC	III	Lam et al[85]
Nivolumab	Regorafenib	VEGFR	Unresectable recurrent GC and refractory or intolerant to chemotherapy	I	Fukuoka et al[86]
Nivolumab	Anlotinib	VEGFR	Unresectable or metastatic GC patients who failed standard therapy	II	Wu et al[87]
Pembrolizumab	Cabozantinib	VEGFR	Refractory metastatic GC	II	Dayyani et al[88]
Pembrolizumab	Ramucirumab	VEGFR-2	Previously treated advanced GC	I	Herbst et al[89]
Nivolumab	Relatlimab	Lymphocyte activation gene-3	Unresectable stage II/stage III GC	II	Kelly et al[90]
Nivolumab	Mogamulizumab	C-C chemokine receptor 4	Unable to have standard operation, refused standard preoperative chemotherapy, electrocorticography performance status 0 or 1	I	Jinushi et al[91]
Nivolumab	Bemarituzumab	FGFR	Previously untreated advanced GC with FGFR2b overexpression	Ib/II	Wainberg et al[92]

FGFR: Fibroblast growth factor receptor; GC: Gastric cancer; GC/GEJ: Gastric cancer/gastroesophageal junction; HER-2: Human epidermal growth factor receptor 2; VEGFR: Vascular endothelial growth factor receptor.